Menu Search
Equities

Mydecine Innovations Group Inc

MYCOF:PKC

Mydecine Innovations Group Inc

Actions
  • Price (USD)0.0076
  • Today's Change0.00 / 0.00%
  • Shares traded209.00
  • 1 Year change-95.98%
  • Beta--
Data delayed at least 15 minutes, as of Jun 14 2024 20:29 BST.
More ▼
Improved Notifications for Markets Data Alerts
Improved Notifications for Markets Data Alerts
Want push notifications sent directly to your devices for equity price changes and breaking news stories? Let us know here.
 
Existing alertsView our existing alerts
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

Mydecine Innovations Group Inc. is a Canada-based biopharmaceutical company. The Company’s principal activities are research, drug development and clinical trials of psilocybin products. The Company offers healthcare professionals a variety serotonin-modulating medications by developing drug families derived from Psilocybin and MDMA. The Company is developing several prodrug families, beginning with a psilocybin-derived smoking cessation drug undergoing a NIDA-funded trial at Johns Hopkins University. It is also developing MYCO-006, short-acting chemical analogs derived from MDMA for treating various conditions, including anxiety and pain. It utilizes artificial intelligence (AI) and pharma research infrastructure at the University of Alberta to develop and manufacture new medications to make them accessible to the general public upon Health Canada and Food and Drug Administration (FDA) approval.

  • Revenue in CAD (TTM)0.00
  • Net income in CAD-18.07m
  • Incorporated2013
  • Employees3.00
  • Location
    Mydecine Innovations Group Inc1890-1075 West Georgia StreetVANCOUVER V6E 3C9CanadaCAN
  • Phone+1 (604) 687-2038
  • Fax+1 (778) 372-1790
  • Websitehttps://www.mydecine.com/
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.